Finasteride and Dutasteride: What the May 2026 MHRA Suicide Warning Means for UK Patients

The MHRA strengthened finasteride and dutasteride warnings on 11 May 2026 over suicidal thoughts and persistent sexual side effects. 170 reports and 19 fatal suicides over 31 years against several million prescription years means the absolute risk is low but real. The drugs are not banned. Informed consent, screening, and monitoring now matter more than ever. UK help: 999, NHS 111 option 2, Samaritans 116 123.

On 11 May 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a strengthened safety warning for finasteride and dutasteride. The two drugs are widely used in UK men, finasteride for male pattern hair loss (and sometimes for an enlarged prostate at higher doses) and dutasteride for an enlarged prostate. If you have seen the news headlines linking them to suicide, the first thing to know is that this is not new evidence the drugs directly cause suicide. It is a regulatory step based on 31 years of Yellow Card reports, prompting clearer warnings, better consent, and tighter monitoring.

To put it in scale: 170 reports of suicidal thoughts and 19 fatal suicides linked to finasteride over those 31 years, against several million prescription years. The absolute risk is very low. The MHRA still judges it serious enough to act, and rightly so. This guide is for UK men on Propecia, Proscar, Avodart, or Combodart, and the families who saw the headlines. We cover what changed, what to do tonight, and the alternatives.

What changed on 11 May 2026 exactly

The MHRA Drug Safety Update on 11 May 2026 formally strengthened the safety information for both finasteride and dutasteride. For finasteride at both the 1mg hair-loss dose (Propecia, generics) and the 5mg prostate dose (Proscar, generics), the product information now explicitly carries warnings about suicidal thoughts and behaviours, depression, mood changes, and persistent sexual side effects that may continue after stopping the drug. For dutasteride 0.5mg (Avodart, Combodart with tamsulosin), a precautionary warning has been added for the same psychiatric effects, on the basis that it is in the same drug class.

The decision rests on a fresh review of UK Yellow Card data from 1994 through 31 May 2025, alongside aligned action from the European Medicines Agency and similar moves by the FDA and Health Canada. It also builds on previous MHRA reviews going back to 2017 that first flagged these signals. In short: the safety signal has been growing for years and the regulator has now formalised the warning rather than relying on small-print mentions.

How serious is the risk and how do the numbers actually look

Scale matters here, both to avoid panic and to take the warning seriously. The MHRA Yellow Card system logged 170 reports of suicidal ideation and 19 fatal suicides linked to finasteride across 31 years. Against an estimated several million UK men who have taken these drugs over that span, the math works out to roughly 5 to 6 reports per year on average.

In absolute terms, that is a low rate. Each one is a real person, though, and Yellow Card is known to under-report; the true number is almost certainly higher than what gets formally submitted. That is the rationale for the warning. The signal is rare but consistent, and it has held up across decades of data, multiple international regulators, and population studies.

For dutasteride, only 5 reports of suicidal ideation came through, with no fatal suicides, which is why its warning is precautionary rather than primary. Taken together, the pattern is suggestive enough that informed consent now matters more than it used to.

What to do if you are taking finasteride or dutasteride right now

Your next step depends on how you are feeling. Three broad scenarios:

If you feel well mentally and physically, you do not need to stop. Continue your medication as prescribed and flag the new warning at your next routine GP or pharmacy review, just for reassurance.

If you have noticed new symptoms since starting (low mood, loss of interest, anxiety, low libido, erectile dysfunction, or reduced semen volume), contact your GP within the next week to discuss. Do not stop the tablet cold without medical advice unless you are in active crisis.

If you are experiencing thoughts of suicide or self-harm right now, this is an emergency. Stop the tablet, call 999, or ring NHS 111 (option 2 for mental health), or call the Samaritans free on 116 123. You can also walk in to your nearest A and E. None of these will hold the drug against you; they will help.

What is post-finasteride syndrome (PFS) and is it real

Post-finasteride syndrome (PFS) is the term patients use to describe a cluster of symptoms that persist for months or years after stopping finasteride. It typically covers sexual changes (very low libido, erectile dysfunction, reduced semen, sometimes genital numbness), cognitive symptoms (brain fog, memory problems), and ongoing depression or anxiety. UK patient information leaflets now acknowledge that some sexual side effects can persist, and this is part of the May 2026 MHRA action.

The exact mechanism is not fully understood. The leading scientific theory involves disruption of neurosteroids in the brain (allopregnanolone in particular, which finasteride lowers). Whether this fully explains PFS is debated.

PFS is uncommon but real for those affected, and it can be genuinely life-altering. There is no proven cure. Management is supportive: mental health support, careful watch and wait, and lifestyle measures. UK help: the PFS Foundation has resources, the NHS provides talking therapies through IAPT, and your GP can refer to endocrinology or urology if needed.

Should you start finasteride in 2026

Starting finasteride or dutasteride after the May 2026 update needs a more careful conversation than before. For most men with no history of depression, anxiety, or suicidal thoughts, the benefits (slower hair loss, fewer prostate symptoms) can still outweigh the small risk. But informed consent is the key word now.

A good prescriber will ask about your personal and family psychiatric history, walk you through the new warnings, agree a monitoring plan (especially in the first 3 to 6 months), and tell you exactly when to stop and call. Less suitable candidates include men with active depression, recent suicide attempts, or a history of severe mental illness.

For hair loss, alternatives include topical minoxidil 5% (Regaine, over the counter), scalp microneedling, and hair transplant surgery (typically 5,000 to 15,000 pounds in the UK). For BPH, alternatives include tamsulosin as an alpha-blocker on its own, lifestyle changes (less evening fluid, less caffeine, double voiding), and surgical options like TURP or UroLift. Topical finasteride has lower systemic absorption but is not zero risk, and the MHRA warning may extend to topical formulations as evidence grows.

Online clinics and the consent gap

A lot of UK men get their finasteride through online doctor services rather than a face-to-face GP. Names that come up regularly: Pharmica, Hims and Hers UK, Manual, Numan, Boots Online Doctor, LloydsPharmacy Online Doctor. The consent process across these has historically been variable, from genuinely thorough mental health screening to little more than a tick-box.

After the May 2026 MHRA update, all UK prescribers (online or not) are expected to upgrade their consent flow. As a patient you should now look for: a proper mental health questionnaire (history of depression, anxiety, suicidal thoughts, family psychiatric history), a clear leaflet on the new warnings, a defined follow-up plan in the first 3 to 6 months, and unambiguous guidance on when to stop and call.

If your online clinic skips the mental health questions, sells the prescription with no warning leaflet, or has no follow-up, treat that as a red flag. You can always switch to a different prescriber. Your GP is also a perfectly reasonable option for finasteride for hair loss on a private prescription, even though it is not generally on the NHS.

Frequently Asked Questions

Has the MHRA banned finasteride in the UK?

No. Finasteride and dutasteride remain fully available, both on NHS prescription (for prostate enlargement) and on private prescription (for hair loss). What changed in May 2026 is the warning label and the monitoring advice, not the licence. You may notice updated patient information leaflets and longer mental health screening when you next collect or order a prescription.

Should I stop my finasteride tablet tonight?

Only if you are in crisis. If you have new suicidal thoughts, yes, stop and call 999 or Samaritans 116 123. If you have new depression, anxiety, or sexual problems, contact your GP within a week. If you feel well, continue and discuss at your next review. Do not stop cold without medical advice unless you are unwell, because rebound mood changes have been reported in some men.

Is dutasteride safer than finasteride?

Not really. Dutasteride is in the same 5-alpha-reductase inhibitor class. It carries a precautionary warning rather than a primary one because there are fewer Yellow Card reports, but those numbers reflect lower prescribing volume, not lower per-patient risk. Switching from one to the other to dodge psychiatric side effects is not a strategy any UK regulator endorses.

What is post-finasteride syndrome and how common is it?

PFS describes persistent sexual, cognitive, and mood symptoms after stopping finasteride. The MHRA now acknowledges that some sexual side effects can persist. Exact UK prevalence is not known but is considered low (a small fraction of users). For those affected it can be severely life-altering. Management is supportive through your GP, NHS mental health services, and the PFS Foundation.

What are the alternatives to finasteride for hair loss?

Topical minoxidil 5% (Regaine), available over the counter, slow but effective for some men and no systemic risk. Scalp microneedling, either at home with a dermaroller or in a clinic. Hair transplant surgery, definitive but expensive (5,000 to 15,000 pounds in UK clinics typically). Accepting hair loss is also a valid choice and many men prefer it once they understand the trade-offs.

I get my finasteride from an online clinic, what should I check?

Check that the consultation asks about your mental health history (depression, anxiety, suicide), provides clear warnings on suicidal thoughts and persistent sexual side effects, sets out a follow-up or monitoring plan for the first 3 to 6 months, and gives you a clear instruction on when to stop and seek help. If any of these are missing, switch prescriber.

Will the warning extend to topical finasteride or finasteride sprays?

Probably, eventually. Topical formulations have lower systemic absorption but are not zero. The May 2026 MHRA action is based on systemic effects of the drug on the brain. Prescribers should already be applying the same consent and monitoring principles to topical formulations until specific evidence on topical safety is published.

How do I report a side effect to the MHRA?

Through the Yellow Card scheme. Search ‘MHRA Yellow Card’ or go to yellowcard.mhra.gov.uk. Anyone can report (patients, families, healthcare professionals). Reporting is what creates the data that drives warnings like this May 2026 update. Your GP and community pharmacist can also submit on your behalf if you would prefer not to do it yourself.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.